



# Baishideng Publishing Group Co., Limited

Flat C, 23/F., Lucky Plaza,  
315-321 Lockhart Road,  
Wan Chai, Hong Kong, China

## ESPS Peer-review Report

**Name of Journal:** World Journal of Gastroenterology

**ESPS Manuscript NO:** 6840

**Title:** Bone Marrow derived Stem Cells for the treatment of end-stage liver disease

**Reviewer code:** 00504767

**Science editor:** Cui, Xue-Mei

**Date sent for review:** 2013-10-29 18:15

**Date reviewed:** 2013-11-18 09:32

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B (Very good)	<input type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)	<input type="checkbox"/> Grade D: rejected	<input type="checkbox"/> Existed	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)		<input type="checkbox"/> No records	<input type="checkbox"/> Major revision

## COMMENTS TO AUTHORS

Very nice review. The only change that should be made is to clearly state what bone marrow cells will be discussed in the review.



# Baishideng Publishing Group Co., Limited

Flat C, 23/F., Lucky Plaza,  
315-321 Lockhart Road,  
Wan Chai, Hong Kong, China

## ESPS Peer-review Report

**Name of Journal:** World Journal of Gastroenterology

**ESPS Manuscript NO:** 6840

**Title:** Bone Marrow derived Stem Cells for the treatment of end-stage liver disease

**Reviewer code:** 00609371

**Science editor:** Cui, Xue-Mei

**Date sent for review:** 2013-10-29 18:15

**Date reviewed:** 2013-11-29 23:02

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B (Very good)	<input checked="" type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)	<input type="checkbox"/> Grade D: rejected	<input type="checkbox"/> Existed	<input checked="" type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)		<input type="checkbox"/> No records	<input type="checkbox"/> Major revision

## COMMENTS TO AUTHORS

This manuscript reviewed and evaluated the results of 18 clinical trials of BMSCs therapy for the end-stage (cirrhosis) liver disease. This review is valuable and timely, but it will be even better if the authors address the following concerns: 1) Even though the authors have mentioned that it could be of interest to compare the effects of the different types of BMSCs (unsorted MNCs, MSCs, HSCs), they failed to stress that, currently, one of the most important problems is the heterogeneity of source cells (BMSCs). 2) Give a brief conclusion at the end of each major section. 3) Ask a native English speaker to revise the language.



# Baishideng Publishing Group Co., Limited

Flat C, 23/F., Lucky Plaza,  
315-321 Lockhart Road,  
Wan Chai, Hong Kong, China

## ESPS Peer-review Report

**Name of Journal:** World Journal of Gastroenterology

**ESPS Manuscript NO:** 6840

**Title:** Bone Marrow derived Stem Cells for the treatment of end-stage liver disease

**Reviewer code:** 00462683

**Science editor:** Cui, Xue-Mei

**Date sent for review:** 2013-10-29 18:15

**Date reviewed:** 2013-12-09 23:58

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input checked="" type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B (Very good)	<input type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)	<input type="checkbox"/> Grade D: rejected	<input type="checkbox"/> Existed	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)		<input type="checkbox"/> No records	<input type="checkbox"/> Major revision

## COMMENTS TO AUTHORS

The only effective treatment for people with end-stage liver disease is liver transplantation. However, in recent years, transplantation of liver cells and / or stem cell transplantation have become promising strategies for liver regeneration. The short review by Andreone P et al reports the results of the main prospective clinical trials on bone marrow stem cells transplantation in patients with cirrhosis, and discusses the unresolved questions regarding the therapeutic use of bone marrow stem cells to liver cirrhosis.